Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Modafinil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | EDNRB | P24530 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | MC3R | P41968 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Modafinil SCHEMBL3238686 | 1.00 | CYP2D6 (0.44) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| (S)-Modafinil SCHEMBL1403524 | 1.00 | CYP2D6 (0.44) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| Modafinil SCHEMBL1560974 | 1.00 | CYP2D6 (0.44) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| Armodafinil SCHEMBL34489 | 1.00 | CYP2D6 (0.44) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| Modafinil SCHEMBL3908867 | 0.96 | EPHX1 (0.42) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| Modafinil SCHEMBL19025521 | 0.95 | PKM (0.41) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| Modafinil SCHEMBL193837 | 0.95 | CYP2D6 (0.41) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| Modafinil SCHEMBL3914634 | 0.95 | PKM (0.41) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| Modafinil SCHEMBL3921259 | 0.95 | PKM (0.41) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| Modafinil SCHEMBL4957995 | 0.93 | CYP1A2 (0.40) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 17165 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-114008013-B | Treatment of CNS disorders with sleep disorders | 哥本哈根大学 | 2026-05-15 | — | — | CN | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-20260115244-A1 | INJECTABLE NUTRIENT SOLUTION | MARULIS NIKOLAS CARMELO (US) | 2026-04-30 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| US-12594250-B2 | Prevention of accumulated tolerance to stimulant medication for the treatment of ADHD | SWANSON JAMES MARTIN (US) | 2026-04-07 | — | — | US | claimed |
| EP-0594507-A1 | Use of modafinil for the treatment of urinary and fecal incontinence | LABORATOIRE L. LAFON (FR) | 1994-04-27 | — | — | EP | claimed |
| EP-0547952-A1 | Use of modafinil for the manufacture of an antiischemic medicament | LABORATOIRE L. LAFON (FR) | 1993-06-23 | — | — | EP | claimed |
| US-5180745-A | Modafinil or benzhydrylsulfonyl acetamide as stimulants for central nervous systems | LABORATOIRE L. LAFON (FR) | 1993-01-19 | — | — | US | claimed |
| EP-0462004-A2 | New use of modafinil | LABORATOIRE L. LAFON (FR) | 1991-12-18 | — | — | EP | claimed |
| US-4927855-A | Levorotatory isomer of benzhydrylsulfinyl derivatives | LABORATOIRE L. LAFON (FR) | 1990-05-22 | — | — | US | claimed |
| EP-0233106-B1 | (-)-BENZHYDRYLSULFINYLACETAMIDE, PROCESS FOR ITS PREPARATION AND ITS USE IN THERAPY | LABORATOIRE L. LAFON (FR) | 1989-05-31 | — | — | EP | claimed |
| EP-0233106-A1 | (-)-Benzhydrylsulfinylacetamide, process for its preparation and its use in therapy | LABORATOIRE L. LAFON (FR) | 1987-08-19 | — | — | EP | claimed |
| EP-0097071-B1 | BENZHYDRYL SULFINYLACETAMIDE DERIVATIVES AND THEIR THERAPEUTICAL USE | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1985-08-28 | — | — | EP | claimed |
| EP-0097071-A1 | Benzhydryl sulfinylacetamide derivatives and their therapeutical use | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1983-12-28 | — | — | EP | claimed |
| US-4177290-A | CNS ACTIVITY | LABORATOIRE L. LAFON (FR) | 1979-12-04 | — | — | US | claimed |